Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-06-28
2011-06-28
Afremova, Vera (Department: 1653)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S009100
Reexamination Certificate
active
07968104
ABSTRACT:
The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6506399 (2003-01-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6667041 (2003-12-01), Schmidt
patent: 6939852 (2005-09-01), Graham
patent: 7001602 (2006-02-01), Schmidt
patent: 7153514 (2006-12-01), Schmidt
patent: 7429387 (2008-09-01), Schmidt
patent: 7449192 (2008-11-01), Schmidt
patent: 7455845 (2008-11-01), Allen et al.
patent: 7470431 (2008-12-01), Schmidt
patent: 2005/0048084 (2005-03-01), Schmidt
patent: 2005/0112147 (2005-05-01), Schmidt
patent: 2005/0175636 (2005-08-01), Donovan
patent: 2008/0177248 (2008-07-01), Schmidt
patent: 2009/0028974 (2009-01-01), Schmidt
patent: 2009/0068227 (2009-03-01), Schmidt
patent: 2005 234633 (2007-04-01), None
patent: 6-183975 (1994-07-01), None
patent: 8-511537 (1996-12-01), None
patent: WO 95/05842 (1995-03-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 99/03483 (1999-01-01), None
Mertens et al. Acta Neurochirurgica. 1995, vol. 64, pp. 17-25.
Pasricha, et al. Botulinum toxin for achalasia: long-term outcome and predictors of response Gastroenterology. May 1996;110(5):1410-5.
Carpenter, Motor Responses of the Urinary Bladder and Skeletal Muscle inBotulinumIntoxicated Rats, J. Physiol. 1967 188:1-11.
R. Duane Cespedes, C. A. Cross and E. J. McGuire, Modified Ingelman-Sundberg Bladder Denervation Procedure for intractable Urge Incontinence,The Journal of Urology, vol. 156,1744-1747, Nov. 1996.
R. Spernol, P. Riss, Urodynamische Überprüfung der Neuraltherapie bei motorischer und sensorischer ReizblaseGeburtsh. u. Frauenheilk. 42 (1982), 527-529.
M. J. Torrens and H. B. Griffith, The Control of the Uninhibited Bladder by Selective Sacral NeurectomyBritish Journal of Urology(1974), 46, 639-644.
JM Gracies, E. Elovic, J. McGuire, D. Simpson, Traditional Pharmacological Treatments for Spasticity Part I: Local TreatmentsMuscle&Nerve, Supplement 6, 1997, S61 to S91.
J. Borg-Stein, J. Stein, Pharmacology of botulinum toxin and implications for use in disorders of muscle Tone,Journal of Head Trauma RehabilitationSep. 1993, 103-106.
LA Koman, JF Mooney, B. Paterson Smith, Neuromuscular Blockade in the Management of Cerebral Palsy,Journal of Child Neurologyvol. 11 1996, S23-S28.
Abrams, “The Standardisation of Terminology of Lower Urinary Tract Function”, Scand. J Urol. Nephrol, 1988; Supp 114:5-19.
Abrams, The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-committee of the International Continence Society, Neurourology and Urodynamics 2002; 21:167-178.
Scott et al. “Botulinum A toxin injection as a treatment for blepharospasm”, Arch Ophthalmol,1985; 103:347-350.
Ewing et al., “Subtrigonal Phenol Injection for Urge Incontinence Secondary to Detrusor Instability in Females”, British Journal of Urology, 1982, vol. 54, pp. 689-692.
“Treatment How Is Prostate Cancer Treated?”, American Foundation for Urologic Disease, available at http://www.afud.org/conditions/pctreat.html, printed Aug. 5, 2003, pp. 1-2.
“Continence Management”; The Prostate Cancer Charity, available at http://www.prostate-cancer.org.uk/learn/prostateCancer/livingWith/continenceManagement.asp, printed Aug. 8, 2003, pp. 1-6.
“Incontinence & the Prostate”, from Morganstern Urology Clinic & Men's Health Center, Phoenix5, available at http://www.phoenix5.org/Basics/treatsides/incontinence/incontMorganstern.html, printed Aug. 5, 2003, pp. 1-11.
“Prostate Cancer (PDQ®): Treatment”; National Cancer Institute, available at http://www.cancer.gov/cancerinfo/pdq/treatment/prostate, date last modified Jul. 17, 2003, pp. 1-11.
“Prostate Cancer: prostate cancer transrectal biopsies”; available at http://216.239.41.104/search?q=cache:RUEZIFhOxiAJ:www.listure.com/prostate-cancer/pro..., printed Aug. 20, 2003, pp. 1-9.
“Prostate Cancer: Tumor Grading”; University of Pittsburgh Medical Center Cancer Centers, available at http://www.upmccancercenters.com/cancer/prostate/gradingsystems.html, printed Aug. 11, 2003, pp. 1-2.
“Prostate Cancer: What are the Treatment Options?”; NSW Health, publication No. BHC-6055, available at http://www.mhcs.health.nsw.gov.au/health-public-affairs/mhcs/publications/6055.html, publication date Jan. 4, 2002, pp. 1-2.
“Prostate Gland and Urinary Problems”; Better Health Channel, available at http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Prostate—gland—and—urinary—p..., article publication date Oct. 10, 2001, pp. 1-4.
“Questions and Answers About the Prostate-Specific Antigen (PSA) Test”; National Cancer Institute, available at http://cis.nci.nih.gov/fact/5—29.htm, date reviewed Jan. 11, 2001, pp. 1-5.
“Symptoms & Treatments Bladder Management in Multiple Sclerosis”; Multiple Sclerosis International Federation, available at http://www.msif.org/en/symptoms—treatments/ms—by—topic/continence/articles/bladder—man... printed Sep. 30, 2003, pp. 1-6.
“The Side Effects of Treatment”; Varian Medical System, available at http://www.varian.com/pti/cty102c.html, printed Aug. 5, 2003, pp. 1-2.
“Treating Prostate Disease”; The Cleveland Clinic, available at http://www.clevelandclinic.org/quality/08-12/08-12c.htm, dated Jan. 28, 1999, pp. 1-3.
“Understanding Gleason Grading”; Phoenix5, available at http://www.phoenix5.org/Infolink/GleasonGrading.html, last revised May 14, 1997, pp. 1-6.
“Western Multiple Sclerosis Center's Glossary”; UW Medicine, available at http://216.239.53.104/search?q=cache:tbApZaM3—5kJ:www.washington.edu/medicine/patien..., printed Sep. 30, 2003, pp. 1-15.
1996 MIMS Annual, Australian Edition. p. 5-372 to 5-373.
Amarenco, “Pour la practiqe” Lae Revue du Praticien (Paris) 1995 45:343-45.
Amarenco, “Evaluation et Traitment des Dysfoctionnements Vesico-Sphincteriens Neurogenes” Annales d'Urologie 27 (1993) pp. 313-320.
Araki et al. Detrusor-Sphincter Dyssynergia with Special Reference to its Diagnosis and Treatment, J. Saitama Med. School, 1992, 23-27, vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama, Japan (partial translation).
Bardsley; “The Neurogenic Bladder”; Nursing Standard, vol. 14, No. 22, accepted Jan. 7, 2000, pp. 39-41.
Beleggia et al., “L'impiego della tossina botulinica tipo A nel trattamento della dissinergia detrusore sfintere” Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract).
Burnstein et al.; “Prostatitis: A Difficult Diagnosis”; available at http://216.239.41.104/search?q=cache:BPKH0claaYAJ:wwww.jaybursteinmd.com/uro/jaydbur..., printed Aug. 20, 2003, pp. 1-3.
“Bladder Problems Explained”, Pfizer, Ltd., available at http://www.bladderzone.com/info/bladder—expl.htm, printed Oct. 20, 2005 (Copyright 2003), pp. 1-2.
Borodic and Pearce, “New Concepts in Botulinum Toxin Therapy”, Drug Safety 11 (1994), pp. 145 to 152.
Boyd, et al., “Transient urinary incontinence after botulinum A toxin” Lancet 1996 348:481-82.
Bruschini et al., “Neurologic control of prostatic secretion in the dog.” Invest. Urol., 15(4):288-290 (1978).
Bulau, Itherapeutische Perspektiven mit Botu
Abel Kenton
Afremova Vera
Allergan Inc.
Condino Debra
Nassif Claude
LandOfFree
Use of neurotoxin therapy for treatment of urologic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of neurotoxin therapy for treatment of urologic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of neurotoxin therapy for treatment of urologic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678730